- Home
- SGMO vs DBI Comparison
SGMO vs DBI Comparison
Compare SGMO & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- DBI
- Stock Information
- Founded
- SGMO 1995
- DBI 1991
- Country
- SGMO United States
- DBI United States
- Employees
- SGMO N/A
- DBI N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- DBI Clothing/Shoe/Accessory Stores
- Sector
- SGMO Health Care
- DBI Consumer Discretionary
- Exchange
- SGMO Nasdaq
- DBI Nasdaq
- Market Cap
- SGMO 122.8M
- DBI 138.7M
- IPO Year
- SGMO 2000
- DBI 1991
- Fundamental
- Price
- SGMO $0.68
- DBI $3.60
- Analyst Decision
- SGMO Strong Buy
- DBI Hold
- Analyst Count
- SGMO 7
- DBI 2
- Target Price
- SGMO $5.29
- DBI $4.50
- AVG Volume (30 Days)
- SGMO 5.4M
- DBI 1.2M
- Earning Date
- SGMO 11-11-2025
- DBI 09-09-2025
- Dividend Yield
- SGMO N/A
- DBI 5.56%
- EPS Growth
- SGMO N/A
- DBI N/A
- EPS
- SGMO N/A
- DBI N/A
- Revenue
- SGMO $81,706,000.00
- DBI $2,917,437,000.00
- Revenue This Year
- SGMO $28.47
- DBI N/A
- Revenue Next Year
- SGMO N/A
- DBI $2.53
- P/E Ratio
- SGMO N/A
- DBI N/A
- Revenue Growth
- SGMO 565.52
- DBI N/A
- 52 Week Low
- SGMO $0.41
- DBI $2.18
- 52 Week High
- SGMO $3.18
- DBI $7.08
- Technical
- Relative Strength Index (RSI)
- SGMO 66.82
- DBI 42.79
- Support Level
- SGMO $0.65
- DBI $3.45
- Resistance Level
- SGMO $0.73
- DBI $3.61
- Average True Range (ATR)
- SGMO 0.06
- DBI 0.20
- MACD
- SGMO 0.02
- DBI -0.10
- Stochastic Oscillator
- SGMO 67.74
- DBI 14.41
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.